Clinical Trial Update: RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating RC48 (disitamab vedotin) in combination with toripalimab as neoadjuvant therapy for cisplatin-ineligible muscle-invasive bladder canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• RC48 (disitamab vedotin) (disitamab vedotin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1, Phase 2 | Status: RECRUITING